Completed trials                     

We have leveraged our local research infrastructure and expertise to lead or contribute to multiple clinical trials conducted through the Resuscitation Outcomes Consortium (ROC), the Strategies to Innovate EmeRgENcy Care Clinical Trials Network (SIREN), and other local, national and international research collaborations. 

Selected completed trials include:

The Inhaled Nitric Oxide After Out-of-Hospital Cardiac Arrest (iNOOHCA) trial enrolled comatose adult survivors of out-of-hospital cardiac arrest and compared inhaled nitric oxide (iNO) 20 ppm administered over 12h versus placebo.  The trial is completed but results are not yet published.

The TTM2 trial enrolled comatose adult survivors of out‑of‑hospital cardiac arrest and compared targeted hypothermia at 33 °C with targeted normothermia/fever prevention. The major finding was that hypothermia did not reduce mortality or improve neurological outcomes compared with active fever prevention.

The ROC Continuous vs Interrupted Compressions (CCC) trial enrolled adults with non‑traumatic out‑of‑hospital cardiac arrest and compared continuous chest compressions with asynchronous ventilations to the standard 30:2 compression‑to‑ventilation strategy. The major finding was no significant difference in survival to discharge or favorable neurological outcomes between strategies.

The ROC ALPS trial enrolled adults with shock‑refractory ventricular fibrillation/pulseless VT during out‑of‑hospital cardiac arrest and compared amiodarone, lidocaine, and placebo. The major finding was no overall improvement in survival to discharge or neurological outcome with antiarrhythmics versus placebo, though a benefit from amiodarone was observed in the subgroup with witnessed arrest.

The ROC PRIMED “Analyze Early vs Analyze Later” trial enrolled adults with out‑of‑hospital cardiac arrest and compared brief versus longer initial CPR before rhythm analysis. The major finding was that timing of the first rhythm analysis did not change survival with good functional outcome.

The ROC PRIMED Impedance Threshold Device (ITD) trial enrolled adults with out‑of‑hospital cardiac arrest and compared an active ITD versus a sham device during standard CPR. The major finding was that use of the ITD did not improve survival with favorable neurological function.

The Continuous Neuromuscular Blockade after Cardiac Arrest trial randomized comatose post‑arrest patients undergoing temperature management to 24 h continuous neuromuscular blockade versus usual care. The trial found no improvement in lactate clearance, survival, or neurological outcomes with routine continuous paralysis.

The Amantadine after Cardiac Arrest trial was a multicenter, randomized, double‑blind, placebo‑controlled pilot that enrolled comatose resuscitated patients to test whether amantadine accelerates awakening. The trial did not demonstrate improved awakening or clinical outcomes with amantadine versus placebo.

The ICECAP trial enrolled comatose adult survivors of out‑of‑hospital cardiac arrest and compared different durations of targeted temperature management using a response‑adaptive design to identify the optimal cooling duration. The trial is completed but results are not yet published.